GE Vernova Inc vs Revvity Inc — how do they compare? GE Vernova Inc trades at $1,042 (market cap $269.50B), while Revvity Inc trades at $117.6 (market cap $12.91B). The key difference: GE Vernova Inc is far larger — about 20.9× Revvity Inc's market cap, and Revvity Inc pays the higher dividend (0.24%). Which is the better fit depends on your goals.
| GEV | RVTY | |
|---|---|---|
Market Cap | $269.50B | $12.91B |
Sector | Technology | Technology |
52-Week High | $1.17K | $117.75 |
52-Week Low | $547.96 | $82.26 |
Enterprise Value | $259.17B | $15.23B |
Dividend Yield | 0.2% | 0.24% |
Signals from Pluang's Aura AI — not financial advice
GE Vernova (GEV) trades at $1,039.90, up 4.95% in the last session, supported by strong technical momentum and bullish analyst sentiment. The company reported mixed Q2 2026 earnings with a miss on EPS expectations but maintains robust revenue growth and a massive $176 billion backlog. Valuation metrics remain elevated with a P/E of 29.01 and EV/EBITDA of 86.33, reflecting high growth expectations tied to AI-driven power demand.
Outlook remains positive given GEV's strategic positioning in AI infrastructure and energy transition, though premium valuation and execution risks on backlog conversion warrant caution. Strong institutional support with 76% buy ratings and consensus price target of $1,270 suggests upside potential, but investors should monitor quarterly execution against high expectations.
RVTY trades at $117.88, up 1.6% today, with a bullish technical outlook and strong earnings momentum after beating Q2 2026 EPS estimates. The stock is near the consensus price target of $120.50, supported by a 51.72% analyst buy rating. Recent news highlights product launches like the SuperFlex prenatal system and investor conference participation, reinforcing growth prospects in diagnostics and biotech tools.
The outlook remains positive with revenue stability and margin strength, but elevated P/E of 55.64 poses valuation risk. Key opportunities include diagnostic demand and AI-driven workflows, while risks involve competitive pressures and execution challenges. Net cash flow turned positive in 2026, signaling improved financial health.
Trailing returns across standard periods
Latest headlines on both assets
GE Vernova is a global leader in the electric power industry. It provides sustainable energy solutions across gas, wind, and hydro sectors, focusing on modernizing the world's power grids.
Read more on GEV →Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →